Ocular Graft versus host Disease - Pipeline Insight, 2024

This Ocular Graft-versus-host Disease - Pipeline Insight, 2024,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Ocular Graft-versus-host Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Ocular Graft-versus-host Disease Understanding

Ocular Graft-versus-host Disease: Overview

Graft versus host disease (GVHD) is a common complication of allogeneic stem cell transplantation (allo-SCT). Ocular GVHD develops in approximately 40-60% of patients following allo-SCT and its most common clinical manifestations include keratoconjunctivitis sicca and cicatricial conjunctivitis. Ocular GVHD may lead to severe ocular surface disease, which can significantly diminish quality of life and restrict daily activities. It is thus important to monitor the condition closely since with timely diagnosis, irreversible damage can be avoided.

Ocular Graft-versus-host Disease - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ocular Graft-versus-host Disease pipeline landscape is provided which includes the disease overview and Ocular Graft-versus-host Disease treatment guidelines. The assessment part of the report embraces, in depth Ocular Graft-versus-host Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ocular Graft-versus-host Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ocular Graft-versus-host Disease R&D. The therapies under development are focused on novel approaches to treat/improve Ocular Graft-versus-host Disease.

This segment of the Ocular Graft-versus-host Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ocular Graft-versus-host Disease Drugs
OccuRx: OCX071OCX071 is being investigated for the treatment of ocular inflammation and fibrosis in the front of the eye, including dry eye syndrome and ocular graft versus host disease. OCX071 is the second candidate of OCX071, which has been demonstrated to prevent retinal inflammation at the back of the eye in diabetic retinopathy.

Ocular Graft-versus-host Disease: Therapeutic Assessment

This segment of the report provides insights about the Ocular Graft-versus-host Disease drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ocular Graft-versus-host Disease

There are approx. 5+ key companies which are developing the therapies for Ocular Graft-versus-host Disease. The companies which have their Ocular Graft-versus-host Disease drug candidates in the most advanced stage, i.e. preclinical include OccuRx.

Phases

This report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Ocular Graft-versus-host Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intranasal
• Intrathecal
• Intravenous
• Oral
• Oral/Intravenous
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ocular Graft-versus-host Disease: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ocular Graft-versus-host Disease therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ocular Graft-versus-host Disease drugs.

Ocular Graft-versus-host Disease Report Insights

• Ocular Graft-versus-host Disease Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ocular Graft-versus-host Disease Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ocular Graft-versus-host Disease drugs?
• How many Ocular Graft-versus-host Disease drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ocular Graft-versus-host Disease?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ocular Graft-versus-host Disease therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ocular Graft-versus-host Disease and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Cambium Medical Technologies
• Glia LLC.
• OccuRx
• Ocular Discovery
• Selagine

Key Products

• CAM 101
• PG-101
• OCX071
• Dipyridamole
• SLG-100

This product will be delivered within 2 business days.